NFE2L2 and autosomal dominant polycystic kidney disease: Since repression of NRF2 begins in early ADPKD, restoring NRF2 activity in the early disease stage offers a promising therapeutic window in reducing cyst formation and improving renal function, without triggering the adverse consequences associated with prolonged NRF2 overactivation.